Novartis reveals significant results for Fabhalta in IgAN study at World Congress of Nephrology
Novartis has achieved a major milestone in the treatment of IgA nephropathy (IgAN), reporting a 38.3% reduction in proteinuria in a pivotal Phase III trial. The study, dubbed APPLAUSE-IgAN, tested Fabhalta (iptacopan), an investigational Factor B inhibitor, demonstrating not only effectiveness in reducing protein levels in urine—a key marker for kidney disease progression—but also a […]